Welcome to Francis Academic Press

International Journal of Frontiers in Medicine, 2023, 5(3); doi: 10.25236/IJFM.2023.050316.

Research progress of Eukaryon translation initiation factor 3 in Glioma

Author(s)

Lili Tang, Huanyu Zhao, Haicheng Xia

Corresponding Author:
Haicheng Xia
Affiliation(s)

The 3rd Affilated Teaching Hospital of Xinjiang Medical University (Affiliated Tumor Hospital), Urumqi, 830011, China

Abstract

Glioma is the most common primary intracranial tumour and is characterised by high rates of disability, mortality and recurrence. Despite standard treatments such as surgery and adjuvant post-operative radiotherapy, the overall survival of gliomas remains low due to the presence of the blood-brain barrier and resistance to chemotherapeutic agents. Eukaryotic translation initiation factor 3 (EIF3) is involved in the genetic regulation of a variety of tumourigenesis, development and prognosis. In this review, we have reviewed the recent literature on the regulation of EIF3 expression in glioma and discussed the role of some EIF3 subunits in glioma.

Keywords

Eukaryon translation initiation factor 3, glioma

Cite This Paper

Lili Tang, Huanyu Zhao, Haicheng Xia. Research progress of Eukaryon translation initiation factor 3 in Glioma. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 3: 88-93. https://doi.org/10.25236/IJFM.2023.050316.

References

[1] Feng X, Li J, Liu P. The Biological Roles of Translation Initiation Factor 3b[J]. International Journal of Biological Sciences, 2018, 14(12): 1630–1635.

[2] Liang Hong. Preliminary study on down-regulation of EIF3B expression to inhibit proliferation and promote apoptosis in malignant glioma cells[D]. Third Military Medical University, 2013.

[3] Yin J-Y, Dong Z, Liu Z-Q, et al. Translational control gone awry: a new mechanism of tumorigenesis and novel targets of cancer treatments[J]. Bioscience Reports, 2011, 31(1): 1–15.

[4] Johnson A G, Petrov A N, Fuchs G, et al. Fluorescently-tagged human eIF3 for single-molecule spectroscopy[J]. Nucleic Acids Research, 2018, 46(2): e8–e8.

[5] Grzmil M, Rzymski T, Milani M, et al. An oncogenic role of eIF3e/INT6 in human breast cancer[J]. Oncogene, 2010, 29(28): 4080–4089.

[6] Xu F, Gu J, Wang L, et al. Up-regulation Of EIF3e Is Associated With The Progression Of Esophageal Squamous Cell Carcinoma And Poor Prognosis In Patients[J]. Journal of Cancer, 2018, 9(7): 1135–1144.

[7] Liu Z, Dong Z, Yang Z, et al. Role of eIF3a (eIF3 p170) in intestinal cell differentiation and its association with early development[J]. Differentiation, 2007, 75(7): 652–661.

[8] Rhoads R E, LeFebvre A K, Korneeva N, et al. Translation Initiation Factor eIF4G‐1 Binds to eIF3 Through the eIF3e Subunit[J]. The FASEB Journal, 2006, 20(4).

[9] Hershey J W B. Regulation of protein synthesis and the role of eIF3 in cancer[J]. Brazilian Journal of Medical and Biological Research, 2010, 43(10): 920–930.

[10] Jäkel H, Peschel I, Kunze C, et al. Regulation of p27 Kip1 by mitogen-induced tyrosine phosphorylation [J]. Cell Cycle, 2012, 11(10): 1910–1917.

[11] Pincheira R, Chen Q, Zhang J-T. Identification of a 170-kDa protein over-expressed in lung cancers [J]. British Journal of Cancer, 2001, 84(11): 1520–1527.

[12] Dellas A, Torhorst J, Bachmann F, et al. Expression of p150 in cervical neoplasia and its potential value in predicting survival[J]. Cancer, 1998, 83(7): 1376–1383.

[13] Chen G, Burger M M. p150 expression and its prognostic value in squamous-cell carcinoma of the esophagus [J]. International Journal of Cancer, 1999, 84(2): 95–100.

[14] Kittler R, Putz G, Pelletier L, et al. An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division[J]. Nature, 2004, 432(7020): 1036–1040.

[15] Wang S, Liu Y, Yao M, et al. Eukaryotic Translation Initiation Factor 3a (eIF3a) Promotes Cell Proliferation and Motility in Pancreatic Cancer[J]. Journal of Korean Medical Science, 2016, 31(10): 1586.

[16] Chai R-C, Wang N, Chang Y-Z, et al. Systematically profiling the expression of eIF3 subunits in glioma reveals the expression of eIF3i has prognostic value in IDH-mutant lower grade glioma[J]. Cancer Cell International, 2019, 19(1): 155.

[17] Zang Y, Zhang X, Yan L, et al. Eukaryotic Translation Initiation Factor 3b is both a Promising Prognostic Biomarker and a Potential Therapeutic Target for Patients with Clear Cell Renal Cell Carcinoma [J]. Journal of Cancer, 2017, 8(15): 3049–3061.

[18] Xu F, Xu C-Z, Gu J, et al. Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating β-catenin signaling pathway[J]. Oncotarget, 2016, 7(28): 43401–43411.

[19] Liang H, Ding X, Zhou C, et al. Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits proliferation and promotes apoptosis in glioblastoma cells[J]. Neurological Sciences, 2012, 33(5): 1057–1062.

[20] Zhu P, Tan Q, Jiang W, et al. Eukaryotic translation initiation factor 3B is overexpressed and correlates with deteriorated tumor features and unfavorable survival profiles in cervical cancer patients [J]. Cancer Biomarkers, 2019, 26(2): 123–130.

[21] Ma F, Li X, Ren J, et al. Downregulation of eukaryotic translation initiation factor 3b inhibited proliferation and metastasis of gastric cancer[J]. Cell Death & Disease, 2019, 10(9): 623.

[22] Hao Jinmin. Expression and clinical significance of eukaryotic translation initiation factor 3c in human glioma tissue [J]. Journal of Brain and Neurological Disorders, 2015, (23(3)): 169-172.

[23] Zhao Qian. Database based analysis of the expression and clinical significance of human EIF3C in head and neck squamous cell carcinoma[J]. Modern medical oncology, 2019, (27(21)): 3789-3793.

[24] Hao J, Wang Z, Wang Y, et al. Eukaryotic initiation factor 3C silencing inhibits cell proliferation and promotes apoptosis in human glioma[J]. Oncology Reports, 2015, 33(6): 2954–2962.

[25] Lin Yaying. A preliminary study on the high expression of eukaryotic translation initiation factor 3 subunit D (EIF3D) and the development of ovarian cancer[D]. Shanghai Jiaotong University, 2016.

[26] Li H, Zhou F, Wang H, et al. Knockdown of EIF3D suppresses proliferation of human melanoma cells through G2/M phase arrest: EIF3D Inhibition in Melanoma[J]. Biotechnology and Applied Biochemistry, 2015, 62(5): 615–620.

[27] Ren M, Zhou C, Liang H, et al. RNAi-Mediated Silencing of EIF3D Alleviates Proliferation and Migration of Glioma U251 and U87MG Cells[J]. Chemical Biology & Drug Design, 2015, 86(4): 715–722.

[28] Pan X-W, Chen L, Hong Y, et al. EIF3D silencing suppresses renal cell carcinoma tumorigenesis via inducing G2/M arrest through downregulation of Cyclin B1/CDK1 signaling[J]. International Journal of Oncology, 2016, 48(6): 2580–2590.

[29] Ren M, Zhou C, Liang H, et al. RNAi-Mediated Silencing of EIF3D Alleviates Proliferation and Migration of Glioma U251 and U87MG Cells [J]. Chemical Biology & Drug Design, 2015, 86(4): 715–722.

[30] Bertorello J, Sesen J, Gilhodes J, et al. Translation reprogramming by eIF3 linked to glioblastoma resistance [J]. NAR Cancer, 2020, 2(3): zcaa020.

[31] Zhao Chang. Preliminary investigation of eukaryotic translation initiation factor in glioma[D]. Southwest Medical University, 2022.